The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

MPN Advances Day 2019 | Immunotherapy for MPNs: where do we stand?

Name: Immunotherapy for MPNs: where do we stand?
Uploaded: 2019-11-15T00:00:00.000Z
Duration: 1 min 27 s
Description: Bethan Psaila, MBBS, MRCP, FRCPath, PhD, University of Oxford, Oxford, UK, gives an overview of where we currently stand with immunotherapy in myeloproliferative neoplasms (MPNs), highlighting an exciting new potential target. This interview took place at the MPN Advances Day 2019 in London, UK.

Bethan Psaila • 15 Nov 2019

MPN Advances Day 2019

Myeloproliferative Neoplasms

Bethan Psaila, MBBS, MRCP, FRCPath, PhD, University of Oxford, Oxford, UK, gives an overview of where we currently stand with immunotherapy in myeloproliferative neoplasms (MPNs), highlighting an exciting new potential target. This interview took place at the MPN Advances Day 2019 in London, UK.